SynthesisMedicine2016
Prognostic value of GLUT-1 expression in oral squamous cell carcinoma: A prisma-compliant meta-analysis.
Synthesis in Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 24 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Prognostic value of glycolysis markers in head and neck squamous cell carcinoma: a meta-analysis.Aging · 2021Pooled it
- Glycolytic pathway candidate markers in the prognosis of oral squamous cell carcinoma: a systematic review with meta-analysis.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2021Pooled it
- Associations between GLUT expression and SUV values derived from FDG-PET in different tumors-A systematic review and meta analysis.PloS one · 2019Pooled it
- Clinicopathological and prognostic significance of GLUT1 in breast cancer: A meta-analysis.Medicine · 2018Pooled it
- Pooled it
- TCGA-Informed Spatial Profiling Reveals Peripheral CD147 Expression at the Invasive Tumor Front as a Prognostic Indicator in OSCC.International journal of molecular sciences · 2026Article
- Glucose-transporter 1 (GLUT1) as a prognostic biomarker: evidence from 14,966 human tumors across 134 cancer types.BMC cancer · 2026Article
- Plumbagin targets the GLUT1/MMP-2 axis to inhibit oral squamous cell carcinoma progression.Cancer cell international · 2025Article
- The Possibility of Plasma Membrane Transporters as Drug Targets in Oral Cancers.International journal of molecular sciences · 2025Review
- Metabolic biomarker in oral squamous cell carcinoma - a comprehensive review.GMS Interdisciplinary plastic and reconstructive surgery DGPW · 2025Review
- Aspartate-β-hydroxylase and hypoxia marker expression in head and neck carcinomas: implications for HPV-associated tumors.Infectious agents and cancer · 2024Article
- Tumour response to hypoxia: understanding the hypoxic tumour microenvironment to improve treatment outcome in solid tumours.Frontiers in oncology · 2024Review
- Article
- Assessment of the association of OCT3/4 with GLUT1 and CD105 in oral squamous cell carcinoma using dual immunohistochemistry.BMC oral health · 2022Observational
- Overexpression of miR-340 inhibits cell proliferation and induces apoptosis of human bladder cancer via targeting Glut-1.BMC urology · 2021Article
- Metabolic Classification and Intervention Opportunities for Tumor Energy Dysfunction.Metabolites · 2021Review
- Current Understanding of the HIF-1-Dependent Metabolism in Oral Squamous Cell Carcinoma.International journal of molecular sciences · 2020Review
- Immunometabolism: new insights and lessons from antigen-directed cellular immune responses.Seminars in immunopathology · 2020Review
- CD147 promotes glucose metabolism, invasion and metastasis via PI3K/AKT pathway in oral squamous cell carcinomas.Translational cancer research · 2019Article
- Tobacco and oral squamous cell carcinoma: A review of carcinogenic pathways.Tobacco induced diseases · 2019Article
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA variety of studies have evaluated the correlation between glucose transporter-1 (GLUT-1) expression and prognosis of oral squamous cell carcinoma (OSCC); however, the results were inconsistent and inconclusive. A meta-analysis was performed to assess the prognostic significance of GLUT-1 in OSCC.
methodsElectronic databases of PubMed, Embase, and Web of Science were searched for relevant studies. The last search was updated on July 2016. Odds ratio (OR) and 95% confidence interval (CI) were pooled to evaluate the relationship between GLUT-1 and clinical features and hazard ratio (HR) and 95% CI were combined to measure the effect of GLUT-1 on overall survival (OS). P value < 0.05 was considered as statistically significant.
resultsA total of 13 studies with 1301 subjects were included for meta-analysis. The pooled data showed that high GLUT-1 expression was associated with advanced tumor stages (n = 7, OR = 2.99, 95% CI: 2.01-4.46, P < 0.001), higher tumor grade (n = 5, OR = 3.34, 95%CI: 1.12-9.94, P = 0.031), tumor size (n = 5, OR = 3.36, 95%CI: 2.04-5.51, P < 0.001), lymph node metastasis (n = 5, OR = 3.15, 95%CI: 1.89-5.25, P < 0.001), tobacco use (n = 3, OR = 2.18, 95%CI: 1.18-4.01, P = 0.013), and distant metastasis (n = 2, OR = 3.06, 95%CI: 1.19-7.9, P = 0.02). Furthermore, increased GLUT-1 expression was also correlated with shorter OS (n = 8, HR = 1.88, 95%CI: 1.51-2.33, P < 0.001). No significant publication bias was detected in this meta-analysis.
conclusionGLUT-1 overexpression was in connection with aggressive clinical features and worse OS in OSCC. However, further studies are still needed to verify whether GLUT-1 could serve as a prognostic biomarker for OSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.